Applicant: Emile Loria et al. U.S. Serial No: 09/867,159

Filed: May 29, 2001

Page: 2

Please amend the application as follows:

In the Claims:

For the Examiner's convenience, Applicants present all pending claims with status

indicators.

Claims 1 to 63. (Canceled)

Claim 64. (Withdrawn) A use of a first allergen or of an isolated nucleic acid molecule

comprising at least one polynucleotide sequence encoding said first allergen, for

preparing a pharmaceutical composition that is useful for treating or preventing an allergy

caused by a second allergen different from the first allergen.

Claim 65. (Withdrawn) The use as claimed in claim 64, wherein said first allergen is a

cystine protease of an acarid.

Claim 66. (Withdrawn) The use as claimed in claim 64, wherein said first allergen is a

cystine protease of an acarid, and said second allergen is not a cystine protease of said

acarid.

Claim 67. (Withdrawn) The use as claimed in claim 64, wherein said first allergen is a

cystine protease of a mite.

Claim 68. (Withdrawn) The use as claimed in claim 64, wherein said first allergen is at

least one peptide epitope of a cystine protease.

Claim 69. (Withdrawn) The use as claimed in claim 68, wherein said first allergen is at

least one peptide epitope of a cystine protease having the sequence SEQ ID NO: 2.

Applicant: Emile Loria et al. U.S. Serial No: 09/867,159

Filed: May 29, 2001

Page: 3

Claim 70. (Withdrawn) The use as claimed in claim 68, wherein said first allergen is a peptide or a mixture of peptide which are chosen from the group consisting of the peptides having the sequence SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5.

Claim 71. (Withdrawn) The use as claimed in claim 67, wherein said first allergen is natural and is obtained by extraction of D. Pteronyssinus and/or D. Ferinae from mites

Claim 72. (Withdrawn) The use as claimed in claim 67, wherein said second allergen is not a cystine protease of said mite.

Claim 73. (Withdrawn) A method for making a pharmaceutical composition that is useful for treating an allergy caused by a first allergen comprising the steps of:

providing a second allergen different from said first allergen or an isolated nucleic acid molecule comprising at least one polynucleotide sequence encoding said second allergen; and

preparing said pharmaceutical composition from said second allergen or said isolated nucleic acid molecule

Claim 74. (New) An anti-allergic pharmaceutical composition comprising

- (a) an acarid allergen comprising
 - i. the allergen encoded by the polynucleotide of SEQ ID NO:1.
 - ii. the allergen as shown in SEO ID NO:2,
 - iii. the allergen as shown in SEQ ID NO:3,
 - iv. the allergen as shown in SEQ ID NO:4, and/or
 - v. the allergen as shown in SEQ ID NO:5.

Applicant: Emile Loria et al. U.S. Serial No: 09/867,159

Filed: May 29, 2001

Page: 4

- (b) an antihistamine selected from the group consisting of brompheniramine, cetirizine, fexofenadine, cyproheptadine, dexchlorpheniramine, hydroxizine, ketotifene, loratidine, mequitazine, oxotomide, mizolastine, ebastine, astemizole, carbinoxamide, alimemazine, buclizine, cyclizine hydrochlorate and doxylamine,
- (c) an inhibitor of histamine synthesis comprising an inhibitor of histadine decarboxylase, and
- (d) a pharmaceutically acceptable carrier.

Claim 75. (New) The pharmaceutical composition of claim 74, wherein the acarid allergen is D. Pteronyssinus.

Claim 76. (New) The pharmaceutical composition of claim 74, wherein the acarid allergen is D. Farinae.

Claim 77. (New) The pharmaceutical composition of claim 74, wherein the acarid allergen is a cystine protease.

Claim 78. (New) The pharmaceutical composition of claim 82, wherein the inhibitor of histadine decarboxylase is tritoqualine.

Claim 79. (New) A method for reducing an allergic reaction comprising administration of the pharmaceutical composition of claim 74 to a subject.

Claim 80. (New) The method of claim 79, wherein reducing the allergic reaction treats allergic hypersensitivity in the subject.

Claim 81. (New) The pharmaceutical composition of claim 74, wherein the acarid allergen is present in an amount of 1 to 1500 micrograms or 10 to 150 micrograms.

Mandel & Adriano Fax:626-395-0694 Mar 17 2005 16:05 P.08

Applicant: Emile Loria et al. U.S. Serial No: 09/867,159

Filed: May 29, 2001

Page: 5

Claim 82. (New) The pharmaceutical composition of claim 74, wherein the antihistamine is present in an amount of 1 to 2000 milligrams or 5 to 200 milligrams.

Claim 83. (New) The pharmaceutical composition of claim 74, wherein the inhibitor of histamine synthesis is present in an amount of 1 to 2000 milligrams, 5 to 200 milligrams or 10 to 300 milligrams.